Last $11.42 USD
Change Today -0.12 / -1.04%
Volume 145.0K
As of 8:10 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

staar surgical co (STAA) Snapshot

Open
$11.48
Previous Close
$11.54
Day High
$11.80
Day Low
$11.24
52 Week High
04/23/14 - $19.74
52 Week Low
08/7/14 - $10.43
Market Cap
440.7M
Average Volume 10 Days
186.6K
EPS TTM
$-0.08
Shares Outstanding
38.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STAAR SURGICAL CO (STAA)

Related News

No related news articles were found.

staar surgical co (STAA) Related Businessweek News

No Related Businessweek News Found

staar surgical co (STAA) Details

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company offers implantable collamer lenses (ICL) comprising Visian ICL to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also provides intraocular lenses (IOL) that include aspheric IOLs that produce a clearer image than traditional spherical lenses; nanoFLEX IOL, a single piece collamer aspheric optic; Toric IOL for cataract patients to treat pre-existing astigmatism; and Preloaded Injector, a silicone or acrylic IOL preloaded into a single-use disposable injector. In addition, the company sells surgical products and other related instruments and devices; and manufactures AquaFlow device for the treatment of glaucoma. It markets its products to health care providers, including surgical centers, hospitals, managed care providers, health maintenance organizations, group purchasing organizations, and government facilities. The company offers its products primarily under the STAAR, Visian, Collamer, CentraFlow, AquaPort, nanoFLEX, nanoPOINT, Epiphany, and AquaFlow names. It distributes its products through its sales representatives, independent sales representatives, and local distributors worldwide. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

staar surgical co (STAA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $638.3K
Chief Financial Officer and Vice President
Total Annual Compensation: $122.0K
President of Europe, Middle East, Africa and ...
Total Annual Compensation: $347.1K
Vice President, Corporate Compliance Officer,...
Total Annual Compensation: $377.4K
Chief Accounting Officer and Vice President
Total Annual Compensation: $334.4K
Compensation as of Fiscal Year 2013.

staar surgical co (STAA) Key Developments

STAAR Surgical Company Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended July 4, 2014; Provides Earnings Guidance for the Year 2014

STAAR Surgical Company announced unaudited consolidated earnings results for the second quarter and six months ended July 4, 2014. For the quarter, the company reported net sales of $20,048,000 compared to $18,164,000 for the same period a year ago. Operating loss was $1,390,000 compared to operating income of $694,000 for the same period a year ago. Loss before income taxes was $1,422,000 compared to income before income taxes of $877,000 for the same period a year ago. Net loss was $1,789,000 or $0.05 per basic and diluted share compared to net income of $278,000 or $0.01 per basic and diluted share for the same period a year ago. Acquisition of property and equipment was $2,269,000 compared to $2,017,000 for the same period a year ago. Adjusted net income (excluding manufacturing consolidation expenses, distribution transition expenses in Spain, gain (loss) on foreign currency transactions, fair value adjustment of warrants, stock-based compensation expense and Toric ICL FDA panel expenses) for the quarter ended July 4, 2014 was $0.3 million, or $0.01 per share versus adjusted net income for the year ago quarter of $1.8 million, or $0.05 per diluted share. Non-GAAP basis adjusted net income for the quarter was $291,000 or $0.01 per diluted share SG&A compared to the adjusted net income of $1.8 million or $0.05 per diluted share reported in the second quarter of 2013. For the six months, the company reported net sales of $40,226,000 compared to $36,165,000 for the same period a year ago. Operating loss was $2,732,000 compared to operating income of $1,778,000 for the same period a year ago. Loss before income taxes was $2,562,000 compared to income before income taxes of $1,663,000 for the same period a year ago. Net loss was $3,148,000 or $0.08 per basic and diluted share compared to net income of $749,000 or $0.02 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $4,064,000 compared to net cash provided by operating activities of $356,000 for the same period a year ago. Acquisition of property and equipment was $2,269,000 compared to $2,017,000 for the same period a year ago. Adjusted net income (excluding manufacturing consolidation expenses, distribution transition expenses in Spain, gain (loss) on foreign currency transactions, fair value adjustment of warrants, stock-based compensation expense and Toric ICL FDA panel expenses) for the first half of 2014 was $1.9 million, or $0.05 per share versus adjusted net income for the year ago first half of 2013 at $5.0 million, or $0.13 per diluted share. Non-GAAP basis the company was in $0.05 and the adjusted income is compared to $0.13 during the first half of 2013 For the year 2014, the company expects revenue growth of 8% to 10%; gross margin expansion of 300 bps, 72.7%; and profitable on a GAAP basis.

STAAR Surgical Company Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 01:20 PM

STAAR Surgical Company Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 01:20 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Barry G. Caldwell, Chief Executive Officer, President and Director, Hans-Martin Blickensdoerfer, President of Europe, Middle East, Africa and Latin America, Stephen P. Brown, Chief Financial Officer and Vice President.

STAAR Surgical Company to Report Q2, 2014 Results on Jul 31, 2014

STAAR Surgical Company announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STAA:US $11.42 USD -0.12

STAA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for STAA.
View Industry Companies
 

Industry Analysis

STAA

Industry Average

Valuation STAA Industry Range
No financial data is available for STAA.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STAAR SURGICAL CO, please visit www.staar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.